Age as an Independent Factor in the Permanent Chemotherapy-Induced Amenorrhea Incidence in Breast Cancer Patients at Dr. Moewardi Hospital, Surakarta, Indonesia

Mudib Mudib; Kristanto Yuli Yarso; Henky Agung Nugroho

doi:10.3889/oamjms.2021.6712

Authors

Mudib Mudib Department of Surgery, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia
Kristanto Yuli Yarso Department of Surgery, Division of Oncology, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia https://orcid.org/0000-0003-4514-4676
Henky Agung Nugroho Department of Surgery, Division of Oncology, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia https://orcid.org/0000-0003-3639-6900

DOI:

https://doi.org/10.3889/oamjms.2021.6712

Keywords:

Age, Permanent, Chemotherapy-induced amenorrhea, Breast cancer

Abstract

Background: Chemotherapy Induced Amenorrhea (CIA) is one common side effect of chemotherapy in breast cancer patients. Some who have CIA may experience menstruation return while others experience permanent CIA.

Aim: to examines the factors that contribute to the incidence of persistent CIA in breast cancer patients.

Methods: The population of this retrospective study was new breast cancer patients with premenopausal status when they started receiving chemotherapy at dr Moewardi Hospital Surakarta, Indonesia, from January 2019 to July 2021. To determine the relationship, the chi-square/Fisher’s exact test was performed. Risk factor analysis on the incidence of permanent CIA was carried out by using a bivariate logistic regression test, followed by multivariate analysis.

Results: A number of 105 premenopausal breast cancer patients who received chemotherapy were found. Of these patients, 97 (93.38%) patients experienced CIA and 8 patients (6.62%) continued to menstruate. Of all the subjects having CIA, 49 patients (46.67%) menstruated again while the other 48 (45.71%) had persistent CIA. Age factor has a significant relationship with the incidence of permanent CIA (p =< 0.001), where patients aged > 45 years tend to have permanent CIA incidence with a proportion of 42 patients (87.5%) (p < 0.05). The multivariate analysis showed that age > 45 years (OR = 75.117; 95% CI = 12.671-445.311; p = < 0.001) was the most dominant risk factor associated with the incidence of permanent CIA, while other variables as risk factors for permanent CIA based on multivariate analysis were Stage III (R = 6.677; 95% CI = 1.370-32,545; p = 0.019) compared to stages I and II, and BMI in the normal category (OR = 5.485; 95% CI = 1.083-27.786; p = 0.040) compared to excess BMI. The other variables were not found to be associated with the incidence of permanent CIA.

Conclusion: Age is a major factor associated with permanent CIA incidence. Other factors related to this study are staging and BMI.

Keywords: Age, Permanent, Chemotherapy Induced Amenorrhea, Breast Cancer

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid:33538338 DOI: https://doi.org/10.3322/caac.21660

Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43-6. https://doi.org/10.7314/apjcp.2016.17.s3.43 PMid:27165206 DOI: https://doi.org/10.7314/APJCP.2016.17.S3.43

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210 PMid:25220842 DOI: https://doi.org/10.1002/ijc.29210

Manuaba IB., Wijaya IG. The relationship between immunohistochemical subtypes and age in breast cancer patients at Sanglah General Hospital, Denpasar. E-J Med Udayana. 2017;6(3):1-5. https://doi.org/10.36565/jab.v9i2.210 DOI: https://doi.org/10.36565/jab.v9i2.210

Trieu PD, Mello-Thoms C, Brennan PC. Female breast cancer in Vietnam: A comparison across Asian specific regions. Cancer Biol Med. 2015;12(3):238-45. PMid:26487968

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505-27. PMid:26181261

Moo T, Sanford R, Dang C, Morrow M, Sloan M, Cancer K, et al. Overview of Breast Cancer Therapy. HHS Public Access. 2019;13(3):339-54. DOI: https://doi.org/10.1016/j.cpet.2018.02.006

Tyagi NK, Dhesy-Thind S. Clinical practice guidelines in breast cancer. Curr Oncol. 2018;25 Suppl 1:S151-60. PMid:29910658 DOI: https://doi.org/10.3747/co.25.3729

Rossi L, Stevens D, Pierga JY, Lerebours F, Reyal F, Robain M, et al. Impact of adjuvant chemotherapy on breast cancer survival: A real-world population. PLoS One. 2015;10(7):e0132853. https://doi.org/10.1371/journal.pone.0132853 PMid:26214853 DOI: https://doi.org/10.1371/journal.pone.0132853

Jeon SJ, Lee JI, Jeon MJ, Lee M. Prognostic effects of adjuvant chemotherapy-induced amenorrhea and subsequent resumption of menstruation for premenopausal breast cancer patients. Medicine (Baltimore). 2016;95(14):e3301. https://doi.org/10.1097/md.0000000000003301 PMid:27057900 DOI: https://doi.org/10.1097/MD.0000000000003301

Meng K, Tian W, Zhou M, Chen H, Deng Y. Impact of chemotherapy-induced amenorrhea in breast cancer patients: The evaluation of ovarian function by menstrual history and hormonal levels. World J Surg Oncol. 2013;11:101. https://doi.org/10.1186/1477-7819-11-101 PMid:23688389 DOI: https://doi.org/10.1186/1477-7819-11-101

Torino F, Barnabei A, de Vecchis L, Sini V, Schittulli F, Marchetti P, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol. 2014;89(1):27-42. https://doi.org/10.1016/j.critrevonc.2013.07.007 PMid:23953684 DOI: https://doi.org/10.1016/j.critrevonc.2013.07.007

Sukumvanich P, Case LD, van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: A prospective study. Cancer. 2010;116(13):3102-11. https://doi.org/10.1002/cncr.25106 PMid:20564648 DOI: https://doi.org/10.1002/cncr.25106

Suprasert P, Khunthong P, Somwangprasert A. Prevalence and potential factors related to irreversible chemotherapy-induced amenorrhea in premenopausal breast cancer patients. Asian Pac J Cancer Care. 2020;5(3):167-72. https://doi.org/10.31557/apjcc.2020.5.3.167-172 DOI: https://doi.org/10.31557/apjcc.2020.5.3.167-172

Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer. Fertil Steril. 2012;97(1):154-9. https://doi.org/10.1016/j.fertnstert.2011.10.005 PMid:22192139 DOI: https://doi.org/10.1016/j.fertnstert.2011.10.005

Okanami Y, Ito Y, Watanabe C. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182-8. https://doi.org/10.1007/s12282-011-0256-7 PMid:21394515 DOI: https://doi.org/10.1007/s12282-011-0256-7

Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: A systematic review and meta-analysis. Acta Oncol. 2016;55(6):664-70. https://doi.org/10.3109/0284186x.2016.1155738 PMid:27105082 DOI: https://doi.org/10.3109/0284186X.2016.1155738

Koga C, Akiyoshi S, Ishida M, Nakamura Y, Ohno S, Tokunaga E. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer. 2017;24(5):714-9. https://doi.org/10.1007/s12282-017-0764-1 PMid:28243992 DOI: https://doi.org/10.1007/s12282-017-0764-1

Pourali L, Taghizadeh AK, Ghavamnasiri MR, Khoshroo F, Hosseini S, Asadi M, et al. Incidence of chemotherapy-induced amenorrhea after adjuvant chemotherapy with taxane and anthracyclines in young patients with breast cancer. Iran J Cancer Prev. 2013;6(3):147-50. https://doi.org/10.1016/s0960-9776(19)30106-7 PMid:25250125 DOI: https://doi.org/10.1016/S0960-9776(19)30106-7

Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín- Martorell P, Bermejo B, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: The impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat. 2010;120(1):245-51. https://doi.org/10.1007/s10549-009-0426-x PMid:19575291 DOI: https://doi.org/10.1007/s10549-009-0426-x

Şükür YE, Kıvançlı İB, Özmen B. Ovarian aging and premature ovarian failure. J Turk Ger Gynecol Assoc. 2014;15(3):190-6. https://doi.org/10.5152/jtgga.2014.0022 PMid:25317048 DOI: https://doi.org/10.5152/jtgga.2014.0022

Zaccarelli E, Rossi L, Tomao F, Giordani E, Verrico M, Strudel M, et al. Body mass index (BMI) and amenorrhea in premenopausal breast cancer patients (PBC) treated with adjuvant antracycline and cyclophospamide chemotherapy (CT). Int J Gynecol Cancer. 2014;24:18-9. Available from: https://www.researchgate.net/publication/269407279_BODY_MASS_INDEX_BMI_AND_AMENORRHEA_IN_PREMENOPAUSAL_BREAST_CANCER_PATIENTS_PBC_TREATED_WITH_ADJUVANT_ANTRACYCLINE_AND_CYCLOPHOSPAMIDE_CHEMOTHERAPY_CT. [Last accessed on 2021 Jun 21]. https://doi.org/10.1200/jco.2014.32.15_suppl.e12000 DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.e12000

Lee JH, Shin DS, Kim HA, Kim YH, Paik NS, Moon NM, et al. Recovery of ovarian function with aromatase inhibitors: In young breast cancer patients (<45) with chemotherapy-induced amenorrhea. J Breast Cancer. 2008;11(3):133-8. https://doi.org/10.4048/jbc.2008.11.3.133 DOI: https://doi.org/10.4048/jbc.2008.11.3.133

di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004;15(7):1065-71. https://doi.org/10.1093/annonc/mdh266 PMid:15205200 DOI: https://doi.org/10.1093/annonc/mdh266

Luo Q, Yin N, Zhang L, Yuan W, Zhao W, Luan X, et al. Role of SDF-1/CXCR4 and cytokines in the development of ovary injury in chemotherapy drug induced premature ovarian failure mice. Life Sci. 2017;179:103-9. https://doi.org/10.1016/j.lfs.2017.05.001 PMid:28478265 DOI: https://doi.org/10.1016/j.lfs.2017.05.001

Yarso KY, Bellynda M, Azmiardi A, Wasita B, Heriyanto DS, Astuti I, et al. Chemotherapy negates the effect of SDF1 mRNA to distant metastasis and poor overall survival in breast cancer patients. Asian Pac J Cancer Prev. 2021;22(3):757-66. https://doi.org/10.31557/apjcp.2021.22.3.757 PMid:33773539 DOI: https://doi.org/10.31557/APJCP.2021.22.3.757